

SKYEPHARMA PLC  
Form 6-K  
February 09, 2005

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February, 2005

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

**For Immediate Release**

**9 February 2005**

**SkyePharma PLC ("the Company")  
Notification of Major Interest in Shares**

In accordance with the Companies Act 1985 (as amended) the Company was informed on 8 February 2005 that following a series of market making transactions on 7 February 2005 by Dresdner Kleinwort Wasserstein Securities Limited ("DrKWSL"), Allianz AG and its subsidiaries, which include DrKWSL, had a notifiable interest of 19,388,772 Ordinary Shares, representing 3.1% of the issued share capital of the Company. These Ordinary Shares are registered in the name of DrKWS Nominees Limited.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ Douglas Parkhill

Name: Douglas Parkhill

Title: Company Secretary

Date: February 09, 2005